x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended June 30, 2014
|
|
OR
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from to
|
|
Commission File Number 000-50513
|
Delaware
(State or other jurisdiction of incorporation
or organization)
|
13-3831168
(I.R.S. Employer
Identification No.)
|
420 Saw Mill River Road, Ardsley, New York
(Address of principal executive offices)
|
10502
(Zip Code)
|
Large accelerated filer
x
|
Accelerated filer
o
|
Non-accelerated filer
o
(Do not check if a
smaller reporting company)
|
Smaller Reporting Company
o
|
Class
|
Outstanding at July 31, 2014
|
|
Common Stock, $0.001 par value
per share
|
41,744,929 shares
|
(In thousands, except share data)
|
June 30,
2014
|
December 31,
2013
|
||||||
(unaudited)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$ | 274,599 | $ | 48,037 | ||||
Restricted cash
|
— | 277 | ||||||
Short-term investments
|
331,254 | 225,891 | ||||||
Trade accounts receivable, net of allowances of $914 and $698, as of June 30, 2014 and December 31, 2013, respectively
|
27,027 | 30,784 | ||||||
Prepaid expenses
|
8,272 | 8,398 | ||||||
Finished goods inventory held by the Company
|
30,821 | 25,535 | ||||||
Finished goods inventory held by others
|
580 | 637 | ||||||
Deferred tax asset
|
10,452 | 19,314 | ||||||
Other current assets
|
10,124 | 8,460 | ||||||
Total current assets
|
693,129 | 367,333 | ||||||
Long-term investments
|
121,855 | 93,299 | ||||||
Property and equipment, net of accumulated depreciation
|
15,823 | 16,525 | ||||||
Deferred tax asset
|
84,885 | 107,985 | ||||||
Intangible assets, net of accumulated amortization
|
17,281 | 17,459 | ||||||
Non-current portion of deferred cost of license revenue
|
3,857 | 4,174 | ||||||
Other assets
|
6,487 | 352 | ||||||
Total assets
|
$ | 943,317 | $ | 607,127 | ||||
Liabilities and Stockholders’ Equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$ | 20,660 | $ | 15,922 | ||||
Accrued expenses and other current liabilities
|
34,064 | 37,569 | ||||||
Deferred product revenue—Zanaflex
|
29,462 | 32,090 | ||||||
Current portion of deferred license revenue
|
9,057 | 9,057 | ||||||
Current portion of revenue interest liability
|
225 | 861 | ||||||
Current portion of convertible notes payable
|
1,144 | 1,144 | ||||||
Total current liabilities
|
94,612 | 96,643 | ||||||
Convertible senior notes (due 2021)
|
283,948 | — | ||||||
Non-current portion of deferred license revenue
|
55,099 | 59,628 | ||||||
Put/call liability
|
167 | 147 | ||||||
Non-current portion of revenue interest liability
|
258 | 493 | ||||||
Non-current portion of convertible notes payable
|
2,135 | 3,228 | ||||||
Other non-current liabilities
|
6,719 | 6,635 | ||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Common stock, $0.001 par value. Authorized 80,000,000 shares at June 30, 2014 and December 31, 2013; issued and outstanding 41,072,916 and 40,896,355 shares, including those held in treasury, as of June 30, 2014 and December 31, 2013, respectively
|
41 | 41 | ||||||
Treasury stock at cost (12,420 shares at June 30, 2014 and December 31, 2013)
|
(329 | ) | (329 | ) | ||||
Additional paid-in capital
|
733,265 | 678,686 | ||||||
Accumulated deficit
|
(232,694 | ) | (238,082 | ) | ||||
Accumulated other comprehensive income
|
96 | 37 | ||||||
Total stockholders’ equity
|
500,379 | 440,353 | ||||||
Total liabilities and stockholders’ equity
|
$ | 943,317 | $ | 607,127 |
(In thousands, except per share data)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||||||||
Revenues:
|
||||||||||||||||
Net product revenues
|
$ | 89,719 | $ | 80,125 | $ | 164,182 | $ | 144,209 | ||||||||
Royalty revenues
|
5,146 | 4,664 | 8,937 | 10,180 | ||||||||||||
License revenue
|
2,264 | 2,264 | 4,529 | 4,529 | ||||||||||||
Total net revenues
|
97,129 | 87,053 | 177,648 | 158,918 | ||||||||||||
Costs and expenses:
|
||||||||||||||||
Cost of sales
|
18,899 | 16,935 | 34,428 | 30,418 | ||||||||||||
Cost of license revenue
|
159 | 159 | 317 | 317 | ||||||||||||
Research and development
|
16,448 | 13,216 | 30,970 | 25,736 | ||||||||||||
Selling, general and administrative
|
50,644 | 48,003 | 97,537 | 96,202 | ||||||||||||
Total operating expenses
|
86,150 | 78,313 | 163,252 | 152,673 | ||||||||||||
Operating income
|
10,979 | 8,740 | 14,396 | 6,245 | ||||||||||||
Other expense (net):
|
||||||||||||||||
Interest and amortization of debt discount expense
|
(426 | ) | (749 | ) | (518 | ) | (1,340 | ) | ||||||||
Interest income
|
165 | 166 | 337 | 339 | ||||||||||||
Total other expense (net)
|
(261 | ) | (583 | ) | (181 | ) | (1,001 | ) | ||||||||
Income before taxes
|
10,718 | 8,157 | 14,215 | 5,244 | ||||||||||||
Provision for income taxes
|
(6,033 | ) | (4,247 | ) | (8,825 | ) | (2,472 | ) | ||||||||
Net income
|
$ | 4,685 | $ | 3,910 | $ | 5,390 | $ | 2,772 | ||||||||
Net income per share—basic
|
$ | 0.11 | $ | 0.10 | $ | 0.13 | $ | 0.07 | ||||||||
Net income per share—diluted
|
$ | 0.11 | $ | 0.09 | $ | 0.13 | $ | 0.07 | ||||||||
Weighted average common shares outstanding used in computing net income per share—basic
|
41,032 | 39,960 | 40,985 | 39,896 | ||||||||||||
Weighted average common shares outstanding used in computing net income per share—diluted
|
42,432 | 41,583 | 42,336 | 41,311 |
(In thousands)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||||||||
Net income
|
$ | 4,685 | $ | 3,910 | $ | 5,390 | $ | 2,772 | ||||||||
Other comprehensive income (loss):
|
||||||||||||||||
Unrealized losses on available for sale securities, net of tax
|
14 | (29 | ) | 59 | (8 | ) | ||||||||||
Other comprehensive income (loss), net of tax
|
14 | (29 | ) | 59 | (8 | ) | ||||||||||
Comprehensive income
|
$ | 4,699 | $ | 3,881 | $ | 5,449 | $ | 2,764 |
(In thousands)
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||
Cash flows from operating activities:
|
||||||||
Net income
|
$ | 5,390 | $ | 2,772 | ||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Share-based compensation expense
|
13,373 | 11,471 | ||||||
Amortization of net premiums and discounts on investments
|
1,487 | 1,169 | ||||||
Amortization of debt discount and debt issuance costs
|
157 | — | ||||||
Amortization of revenue interest issuance cost
|
12 | 28 | ||||||
Depreciation and amortization expense
|
3,624 | 2,912 | ||||||
Loss (gain) on put/call liability
|
20 | (329 | ) | |||||
Deferred tax provision
|
8,863 | 2,339 | ||||||
Changes in assets and liabilities:
|
||||||||
Decrease (increase) in accounts receivable
|
3,757 | (728 | ) | |||||
Increase in prepaid expenses and other current assets
|
(1,538 | ) | (1,371 | ) | ||||
Increase in inventory held by the Company
|
(5,287 | ) | (10,820 | ) | ||||
Decrease in inventory held by others
|
57 | 87 | ||||||
Decrease in non-current portion of deferred cost of license revenue
|
317 | 317 | ||||||
Decrease in other assets
|
17 | 17 | ||||||
Increase (decrease) in accounts payable, accrued expenses, other current liabilities
|
134 | (3,942 | ) | |||||
(Decrease) increase in revenue interest liability interest payable
|
(510 | ) | 216 | |||||
Decrease in non-current portion of deferred license revenue
|
(4,528 | ) | (4,528 | ) | ||||
Increase (decrease) in other non-current liabilities
|
18 | (107 | ) | |||||
(Decrease) increase in deferred product revenue—Zanaflex
|
(2,628 | ) | 811 | |||||
Decrease in restricted cash
|
277 | 339 | ||||||
Net cash provided by operating activities
|
23,012 | 653 | ||||||
Cash flows from investing activities:
|
||||||||
Purchases of property and equipment
|
(1,390 | ) | (2,728 | ) | ||||
Purchases of intangible assets
|
(1,286 | ) | (1,664 | ) | ||||
Purchases of investments
|
(263,848 | ) | (59,541 | ) | ||||
Proceeds from maturities of investments
|
128,500 | 60,000 | ||||||
Net cash used in investing activities
|
(138,024 | ) | (3,933 | ) | ||||
Cash flows from financing activities:
|
||||||||
Proceeds from issuance of convertible senior notes
|
345,000 | — | ||||||
Debt issuance costs
|
(7,441 | ) | — | |||||
Proceeds from issuance of common stock and option exercises
|
4,375 | 4,640 | ||||||
Repayments of revenue interest liability
|
(360 | ) | (534 | ) | ||||
Net cash provided by financing activities
|
341,574 | 4,106 | ||||||
Net increase in cash and cash equivalents
|
226,562 | 826 | ||||||
Cash and cash equivalents at beginning of period
|
48,037 | 41,876 | ||||||
Cash and cash equivalents at end of period
|
$ | 274,599 | $ | 42,702 | ||||
Supplemental disclosure:
|
||||||||
Cash paid for interest
|
706 | 1,059 | ||||||
Cash paid for taxes
|
1,214 | 1,337 | ||||||
For the three-month
|
For the six-month
|
|||||||||||||||
period ended June 30,
|
period ended June 30,
|
|||||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Research and development
|
$ | 1.6 | $ | 1.5 | $ | 2.7 | $ | 2.7 | ||||||||
Selling, general and administrative
|
6.0 | 5.0 | 10.7 | 8.8 | ||||||||||||
Total
|
$ | 7.6 | $ | 6.5 | $ | 13.4 | $ | 11.5 |
Number of Shares
(In thousands)
|
Weighted Average
Exercise Price
|
Weighted Average
Remaining
Contractual
Term
|
Intrinsic Value
(In thousands)
|
|||||||||||||
Balance at January 1, 2014
|
6,486 | $ | 25.61 | |||||||||||||
Granted
|
1,625 | 37.31 | ||||||||||||||
Cancelled
|
(129 | ) | 31.31 | |||||||||||||
Exercised
|
(173 | ) | 25.35 | |||||||||||||
Balance at June 30, 2014
|
7,809 | $ | 27.96 | 7.0 | $ | 52,648 | ||||||||||
Vested and expected to vest at June 30, 2014
|
7,709 | $ | 27.87 | 6.9 | $ | 52,477 | ||||||||||
Vested and exercisable at June 30, 2014
|
4,378 | $ | 24.16 | 5.4 | $ | 42,555 |
(In thousands)
Restricted Stock
|
Number of Shares
|
|
Nonvested at January 1, 2014
|
421
|
|
Granted
|
284
|
|
Vested
|
(4)
|
|
Forfeited
|
(20)
|
|
Nonvested at June 30, 2014
|
681
|
(In thousands, except per share data)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||||||||
Basic and diluted
|
||||||||||||||||
Net income
|
$ | 4,685 | $ | 3,910 | $ | 5,390 | $ | 2,772 | ||||||||
Weighted average common shares outstanding used in computing net income per share—basic
|
41,032 | 39,960 | 40,985 | 39,896 | ||||||||||||
Plus: net effect of dilutive stock options and restricted common shares
|
1,400 | 1,623 | 1,351 | 1,415 | ||||||||||||
Weighted average common shares outstanding used in computing net income per share—diluted
|
42,432 | 41,583 | 42,336 | 41,311 | ||||||||||||
Net income per share—basic
|
$ | 0.11 | $ | 0.10 | $ | 0.13 | $ | 0.07 | ||||||||
Net income per share—diluted
|
$ | 0.11 | $ | 0.09 | $ | 0.13 | $ | 0.07 |
(In thousands)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
Denominator
|
||||
Stock options and restricted common shares
|
3,739
|
1,762
|
3,859
|
3,139
|
Convertible note – Saints Capital
|
29
|
39
|
29
|
39
|
(In thousands)
|
Level 1
|
Level 2
|
Level 3
|
|||||||||
June 30, 2014
|
||||||||||||
Assets Carried at Fair Value:
|
||||||||||||
Cash equivalents
|
$ | 253,604 | $ | — | $ | — | ||||||
Short-term investments
|
— | 331,254 | — | |||||||||
Long-term investments
|
— | 121,855 | — | |||||||||
Liabilities Carried at Fair Value:
|
||||||||||||
Put/call liability
|
— | — | 167 | |||||||||
Contingent purchase price
|
— | — | 254 | |||||||||
December 31, 2013
|
||||||||||||
Assets Carried at Fair Value:
|
||||||||||||
Cash equivalents
|
$ | 28,308 | $ | — | $ | — | ||||||
Short-term investments
|
— | 225,891 | — | |||||||||
Long-term investments
|
— | 93,299 | — | |||||||||
Liabilities Carried at Fair Value:
|
||||||||||||
Put/call liability
|
— | — | 147 | |||||||||
Contingent purchase price
|
— | — | 236 |
(In thousands)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||||||||
Put/call liability:
|
||||||||||||||||
Balance, beginning of period
|
$ | 167 | $ | 247 | $ | 147 | $ | 329 | ||||||||
Total realized and unrealized gains included in selling, general and administrative expenses:
|
— | (247 | ) | 20 | (329 | ) | ||||||||||
Balance, end of period
|
$ | 167 | $ | — | $ | 167 | $ | — |
(In thousands)
|
Three-month
period ended
June 30, 2014
|
Three-month
period ended
June 30, 2013
|
Six-month
period ended
June 30, 2014
|
Six-month
period ended
June 30, 2013
|
||||||||||||
Contingent purchase price:
|
||||||||||||||||
Balance, beginning of period
|
$ | 245 | $ | — | $ | 236 | $ | — | ||||||||
Total losses included in selling, general and administrative expenses:
|
9 | — | 18 | — | ||||||||||||
Balance, end of period
|
$ | 254 | $ | — | $ | 254 | $ | — |
(In thousands)
|
Amortized
Cost
|
Gross
unrealized
gains
|
Gross
unrealized
losses
|
Estimated
fair
value
|
||||||||||||
June 30, 2014
|
||||||||||||||||
US Treasury bonds
|
$ | 452,947 | $ | 166 | $ | (4 | ) | $ | 453,109 | |||||||
December 31, 2013
|
||||||||||||||||
US Treasury bonds
|
319,123 | 69 | (2 | ) | 319,190 |
(In thousands)
|
Net Unrealized Gains on Marketable Securities, Net of Tax
|
|||
Balance at December 31, 2013
|
$ | 37 | ||
Other comprehensive income before reclassifications:
|
59 | |||
Amounts reclassified from accumulated other
comprehensive income
|
— | |||
Net current period other comprehensive income
|
59 | |||
Balance at June 30, 2014
|
$ | 96 |
(In thousands)
|
June 30, 2014
|
|||
Liability component:
|
||||
Principal
|
$
|
345,000
|
||
Less: debt discount, net
|
(61,052
|
)
|
||
Net carrying amount
|
$
|
283,948
|
||
Equity component
|
$
|
61,195
|
(In thousands)
|
June 30, 2014
|
|||
Contractual interest expense
|
$
|
116
|
||
Amortization of debt issuance costs
|
14
|
|||
Amortization of debt discount
|
143
|
|||
Total interest expense
|
$
|
273
|
·
|
The first is U.S. Patent No. 8,007,826, with claims relating to methods to improve walking in patients with MS by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. Based on the final patent term adjustment calculation of the United States Patent and Trademark Office, or USPTO, this patent will extend into 2027.
|
·
|
The second is U.S. Patent No. 5,540,938 (“the ‘938 patent”), the claims of which relate to methods for treating a neurological disease, such as MS, and cover the use of a sustained release dalfampridine formulation, such as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg for improving walking in people with MS. In April 2013, the ‘938 patent received a five year patent term extension under the patent restoration provisions of the Hatch Waxman Act. With a five year patent term extension, the ‘938 patent will expire in 2018. We have an exclusive license to this patent from Alkermes (originally with Elan, but transferred to Alkermes as part of its acquisition of Elan’s Drug Technologies business).
|
·
|
The third is U.S. Patent No. 8,354,437, which includes claims relating to methods to improve walking, increase walking speed, and treat walking disability in patients with MS by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. This patent is set to expire in 2026.
|
·
|
The fourth is U.S. Patent No. 8,440,703, which includes claims directed to methods of improving lower extremity function and walking and increasing walking speed in patients with MS by administering less than 15 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. This patent is set to expire in 2025.
|
·
|
The fifth, which issued in March of 2014, is U.S. Patent No. 8,663,685 with claims relating to methods to improve walking in patients with MS by administering 10 mg of sustained release 4-aminopyridine (dalfampridine) twice daily. Absent patent term adjustment, the patent is set to expire in 2024.
|
·
|
We expect 2014 net revenue from the sale of Ampyra to range from $328 million to $335 million.
|
·
|
We expect Zanaflex (tizanidine hydrochloride) and ex-U.S. Fampyra (prolonged-release fampridine tablets) 2014 revenue to be approximately $25 million, which includes net sales of branded Zanaflex products, royalties from ex-U.S. Fampyra and authorized generic tizanidine hydrochloride capsules sales, and $9.1 million in amortized licensing revenue from the $110 million payment we received from Biogen Idec in 2009 for Fampyra ex-U.S. development and commercialization rights.
|
·
|
Research and development (R&D) expenses in 2014 are expected to range from $60 million to $70 million, excluding share-based compensation charges and expenditures related to the potential acquisition of new products or other business development activities.
|
·
|
Selling, general and administrative expenses (SG&A) in 2014 are expected to range from $180 million to $190 million, excluding share-based compensation charges and expenditures related to the potential acquisition of new
|
·
|
In November 2013, we announced that we submitted an NDA filing for Plumiaz to the FDA. In May 2014, the FDA issued a Complete Response Letter, or CRL, for the Plumiaz NDA. We are working with the FDA to finalize the requirements for re-filing the Plumiaz NDA, and are preparing to begin the clinical work that will be necessary for re-submission. Once we have refiled the NDA, we expect that the FDA will respond to our submission within six months. Based on the requirements noted in the letter, we do not expect Plumiaz to receive FDA approval in 2014.
|
·
|
Initiate a Phase 3 clinical trial by the end of this year studying the use of dalfampridine administered twice daily (BID) to improve walking in people who have experienced a stroke. We met with the FDA in December 2013 and we are integrating FDA design recommendations into the study protocol. As part of the trial design, we are planning to conduct an interim analysis of the trial data, and depending on the outcome of that analysis we may initiate a second pivotal trial prior to the conclusion of the Phase 3
trial.
|
·
|
We are planning to pursue treatment of painful HIV-related neuropathy as the first indication for NP-1998, and expect to begin a Phase 3 clinical trial by the end of 2014.
|
·
|
Continue to progress our Phase 1 clinical trial of rHIgM22, which we initiated in April 2013. We have completed the dose escalation portion of this trial, with no serious or limiting adverse events reported. The second portion of this trial is exploring safety, tolerability and efficacy endpoints for six months in additional patients at the two highest doses achieved in the dose escalation portion of the trial. Enrollment in the second portion of this trial is complete. We expect to complete our initial analysis of the Phase 1 clinical trial data in early 2015.
|
·
|
Continue to progress our second clinical trial of GGF2, which we initiated in October 2013. This is a Phase 1b single-infusion trial in people with heart failure that is assessing tolerability of three dose levels of GGF2, which were tested in our first clinical trial of GGF2, and which also includes assessment of drug-drug interactions and several exploratory measures of efficacy. In October 2013, we announced that the first patient was enrolled in this clinical trial. We voluntarily paused enrollment in this trial in December 2013 pending review of additional preclinical data with the FDA. In April 2014, we announced that we had completed this review and agreed with the FDA that the trial will resume recruitment. We expect to complete this trial in the second half of 2015.
|
·
|
Continue to progress our AC105 clinical trial, which is evaluating the safety and tolerability of AC105 in people with traumatic SCI, and also incorporates several exploratory efficacy measures. In September 2013, we announced that the first patient was enrolled in this clinical trial. Recruitment in this trial has been challenging due to several factors, and we are working with the trial centers to address the issues.
|
|
•
|
with respect to Zanaflex net revenues up to and including $30.0 million for each fiscal year during the term of the agreement, 15% of such net revenues;
|
|
•
|
with respect to Zanaflex net revenues in excess of $30.0 million but less than and including $60.0 million for each fiscal year during the term of the agreement, 6% of such net revenues; and
|
|
•
|
with respect to Zanaflex net revenues in excess of $60.0 million for each fiscal year during the term of the agreement, 1% of such net revenues.
|
(In thousands)
|
June 30, 2014
|
|||
Liability component:
|
||||
Principal
|
$
|
345,000
|
||
Less: debt discount, net
|
(61,052
|
)
|
||
Net carrying amount
|
$
|
283,948
|
||
Equity component
|
$
|
61,195
|
Exhibit No
.
|
Description
|
|
1.1
|
Underwriting Agreement dated June 17, 2014. Incorporated herein by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed on June 23, 2014 (filed under the Company’s SEC File Number 000-50513).
|
|
4.1
|
Indenture dated June 23, 2014. Incorporated herein by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed on June 23, 2014 (filed under the Company’s SEC File Number 000-50513).
|
|
4.2
|
First Supplemental Indenture dated June 23, 2014. Incorporated herein by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed on June 23, 2014 (filed under the Company’s SEC File Number 000-50513).
|
|
4.3
|
Form of 1.75% Convertible Senior Note due 2021 (included in Exhibit 4.2). Incorporated herein by reference to Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed on June 23, 2014 (filed under the Company’s SEC File Number 000-50513).
|
|
10.1*
|
Employment offer letter, dated May 4, 2014, by and between the Registrant and Andrew Hindman.
|
|
10.2**
|
Supply Agreement, dated as of June 30 2009, between Biogen Idec International GmbH (“Biogen”) and the Registrant (as subsequently amended by (i) Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 21, 2010, between Biogen and the Registrant, (ii) Amendment #1 to Addendum #1, dated as of May 16, 2011, and (iii) Addendum #2 to the Supply Agreement, dated as of August 28, 2010, between Biogen and the Registrant).
|
|
31.1
|
Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
|
|
31.2
|
Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
|
|
32.1
|
Certification by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
Certification by the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS***
|
XBRL Instance Document
|
|
101.SCH***
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL***
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF***
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB***
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE***
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
Acorda Therapeutics, Inc.
|
||
By:
|
/s/
Ron Cohen
|
|
Date: August 7, 2014
|
Ron Cohen, M.D.
President, Chief Executive Officer and Director
(Principal Executive Officer)
|
By:
|
/s/
Michael Rogers
|
|
Date: August 7, 2014
|
Michael Rogers
Chief Financial Officer
(Principal Financial and Accounting Officer)
|
Exhibit No.
|
Description
|
|
10.1*
|
Employment offer letter, dated May 4, 2014, by and between the Registrant and Andrew Hindman.
|
|
10.2**
|
Supply Agreement, dated as of June 30 2009, between Biogen Idec International GmbH (“Biogen”) and the Registrant (as subsequently amended by (i) Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 21, 2010, between Biogen and the Registrant, (ii) Amendment #1 to Addendum #1, dated as of May 16, 2011, and (iii) Addendum #2 to the Supply Agreement, dated as of August 28, 2010, between Biogen and the Registrant).
|
|
31.1
|
Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
|
|
31.2
|
Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934.
|
|
32.1
|
Certification by the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
32.2
|
Certification by the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS***
|
XBRL Instance Document
|
|
101.SCH***
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL***
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF***
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB***
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE***
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
1.
|
The salary is $400,000 per annum, payable semi-monthly on the 15
th
and the last business day of the month. The semi-monthly rate is $16,666.66. Your salary will be subject to annual review. Your work location will be the Company headquarters in Ardsley, New York.
|
2.
|
You will receive a signing bonus of $100,000.00 in two separate payments. The first payment of $50,000.00 will be paid to you within the first 30 days of your start date. If you voluntarily terminate without Good Reason within the first twelve months of employment, you agree to reimburse the Company on a prorated basis for the first payment of $50,000. The second payment of $50,000.00 will be paid to you on the one-year anniversary of your start date. If you voluntarily terminate without Good Reason twelve months from the date of the second
payment, you agree to reimburse the Company on a prorated basis for the second payment of $50,000.
|
3.
|
Your start date is May 13, 2014.
|
4.
|
You will be eligible to participate in the Company’s benefit plans one month from your hire date. Your benefits will be commensurate with the benefits provided to other senior executives at the Company.
|
5.
|
You will also be eligible to participate in the Company’s 401(k) plan and Flexible Spending Accounts one month from your hire date.
|
6.
|
You shall be entitled to all perquisites offered to senior executives of the Company. In addition, you shall be entitled to reimbursement of all ordinary and reasonable out-of-pocket business expenses which are incurred by you in furtherance of the Company’s business, in accordance with its policies.
|
7.
|
For 2014, you will be eligible for 15 days of paid time off (PTO), all Company-paid holidays including the week the Company is closed between Christmas and New Year’s, and 2 floating holidays. After 2014, you will receive PTO and holidays in accordance with Company policy and commensurate with other senior executives at the Company.
|
8.
|
You will receive a base grant of 138,840 options of Acorda common stock, vesting over four years. In accordance with the Company’s standard option grant procedures, the first 25% of your options will vest at the end of your first 12 months of employment, and the remaining 75% will vest on a quarterly basis over the remaining three years. The grant date will be determined as of the new hire start date. The strike price will be the market price of the stock at the close of business on the date of grant.
|
9.
|
You will also receive 46,280 shares of restricted stock of Acorda common stock, vesting annually over a four-year period as follows: ¼ of the grant will vest on May 13, 2015, ¼ on May 13, 2016, ¼ on May 13, 2017 and ¼ on May 13, 2018. Restricted shares are subject to the additional terms and conditions of the Acorda Restricted Share Certificate approved by the Board.
|
10.
|
You are eligible to receive a special grant of 27,768 options of Acorda common stock vesting after three years on May 13, 2017. The strike price will be the market price of the stock at the close of business on the new hire start date. In addition, you will receive 9,256 shares of restricted stock of Acorda common stock, vesting after three years on May 13, 2017. Restricted shares are subject to the additional terms and conditions of the Acorda Restricted Share Certificate approved by the Board. The options and restricted shares under this special grant will not be subject to 100% vesting in the event of a Change in Control.
|
11.
|
In addition to a year-end performance review, you will be eligible to participate in the Company’s Merit Increase Program, Annual Cash Bonus Program and Acorda Equity Program with a potential to receive a pro-rated merit increase, cash bonus and equity grant. Your Annual Cash Bonus Program target is 50% of base salary and is based on the Company’s performance against the Corporate Goals and individual/team performance against goals established for that bonus year. Bonus targets include a possible range of zero and can exceed 100% for an individual/team goal or in aggregate. Eighty percent of your target is attributed to Company performance and twenty percent is attributed to individual/team performance. The Annual Cash Bonus Program and the Acorda Equity Program are subject to approval by the Board of Directors. These three programs will be pro-rated for your first year of employment or any subsequent partial year of employment.
|
12.
|
You will receive up to three months of temporary housing at one of the Company’s designated properties. You will also receive assistance with permanent housing in New York and commuting expenses to and from California, such as flight accommodations, not to exceed an aggregate $35,000. If within the first twelve months of employment, you voluntarily terminate your employment
|
13.
|
You shall be entitled to the same indemnification and insurance coverage that other senior executive level employees receive pursuant to the Company’s Certificate of Incorporation, Bylaws, customary Indemnification Agreement and insurance policies, all as currently in effect, and applicable law.
|
14.
|
Within the first thirty days of employment, you will be given an Employment Agreement with terms including, but not limited to, terms contained in the Employment Agreement of Michael Rogers dated October 7, 2013.
|
15.
|
To comply with INS regulations, please bring with you on your first day of work, proof verifying your right to work in the United States. Some examples are passport, driver’s license and Social Security card, or certificate of citizenship, etc.
|
16.
|
If you accept employment with the Company, you also certify that the information that you have provided the Company in connection with your submission for employment is true and complete. You understand that if you provided false or misleading information to the Company during the course of the interview or application process it may result in disciplinary action up to and including termination of your employment at any time.
|
17.
|
By accepting this offer, you represent that you are not a party to any employment agreement that would interfere with your employment with Acorda Therapeutics, Inc. If you are a party to any agreement that contains any restrictive provisions (confidentiality, non-compete, or otherwise) that potentially interfere with your employment with Acorda, you must notify me of those agreements and the relevant provisions, and to the extent possible, submit copies of the agreements. This offer is contingent upon a review of these agreements prior to your starting date so that Acorda can make an independent determination for its own purposes (and not to be considered advice to you) regarding the legal restraints in these agreements and whether they prohibit your employment with Acorda.
|
18.
|
This letter is not intended, nor should it be considered, as an employment contract for a definite or indefinite period. Once employed, you will be an employee at will. This letter also constitutes the understanding between us with respect to our offer of employment, and replaces and supersedes any previous understandings or arrangements.
|
/s/ Andrew Hindman |
5
/13/14
|
Signature
|
Date
|
SUPPLY AGREEMENT
|
1
|
|
W I T N E S S E T H:
|
1
|
|
1.
|
DEFINITIONS
|
1
|
2.
|
COORDINATION; SUPPLY CHAIN MANAGEMENT
|
5
|
2.1
|
Relationship Managers
|
5
|
2.2
|
Joint Manufacturing Committee.
|
5
|
2.3
|
Meetings
|
6
|
2.4
|
Decision Making; Authority.
|
6
|
2.5
|
Third Party Manufacturers
|
7
|
3.
|
SUPPLY
|
7
|
3.1
|
Exclusive Supply
|
7
|
3.2
|
General Scope of Services
|
7
|
3.3
|
Quality Agreement
|
7
|
3.4
|
Third Party Manufacturers
|
7
|
4.
|
FORECASTS AND ORDERS
|
8
|
4.1
|
Forecast
|
8
|
4.2
|
Long-Term Forecast.
|
8
|
4.3
|
Amending Forecasts
|
8
|
4.4
|
Launch Stocks
|
9
|
4.5
|
Purchase Orders.
|
9
|
4.6
|
Fulfillment of Purchase Orders
|
9
|
4.7
|
Supply Uncertainty
|
10
|
4.8
|
Safety Stock
|
10
|
5.
|
PRODUCTION
|
11
|
5.1
|
Specifications.
|
11
|
5.2
|
Changes to the Specifications, Processing or the Facility.
|
11
|
5.3
|
Quality Assurance.
|
12
|
12.4
|
No Implied Waivers.
|
21
|
12.5
|
Order of Precedence
|
21
|
12.6
|
Covenant of Further Assurances
|
22
|
12.7
|
Relationship
|
22
|
12.8
|
Severability
|
22
|
12.9
|
Assignment
|
22
|
12.10
|
Force Majeure
|
22
|
12.11
|
Export Compliance
|
22
|
12.12
|
Performance by Affiliates and Third Party Distributors
|
23
|
12.13
|
Counterparts and Facsimile Signatures.
|
23
|
Exhibit A
|
Acorda Supply Agreements
|
1 |
1.
|
DEFINITIONS
|
2.
|
COORDINATION; SUPPLY CHAIN MANAGEMENT
|
3.
|
SUPPLY
|
4.
|
FORECASTS AND ORDERS
|
5.
|
PRODUCTION
|
6.
|
DELIVERY
AND PAYMENT
|
7.
|
REGULATORY
|
10.
|
TERM AND TERMINATION
|
11.
|
GOVERNING LAW
|
12.
|
MISCELLANEOUS
|
ACORDA THERAPEUTICS, INC.
|
BIOGEN IDEC INTERNATIONAL GMBH
|
By: /s/ Ron Cohen
Name: Ron Cohen
Title: Chief Executive Officer
|
By: /s/ Anders Lundstrom
Name: Anders Lundstrom
Title: SVP, Head of Int’l
|
·
|
Amended and Restated License Agreement between Elan Corporation plc and Acorda, dated September 26, 2003
|
·
|
Supply Agreement between Elan Pharma International Limited and Acorda, dated September 26, 2003
|
·
|
Technical Agreement between Elan Pharma International Limited and Acorda, dated December 19, 2005
|
·
|
Patheon Inc. Proposal No. ELN-FQ-0001-1002-RF, entitled “Fampridine Tablets (10mg, 20mg, 25mg) Technical Transfer Program Proposal for Commercial Registration for Acorda Therapeutics, dated February 26, 2003
|
·
|
Elan Consent
|
6.
|
LIABILITY, INDEMNIFICATION
|
BIOGEN IDEC INTERNATIONAL GMBH
By:
/s/Anne M. Nunez
_______________________
Name: Anne M. Nunez
Title: Director, European Operations
|
ACORDA THERAPEUTICS, INC.
By:
/s/ Ron Cohen
___________________
Ron Cohen
President and Chief Executive Officer
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Acorda Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/
Ron Cohen
|
|
Ron Cohen
Chief Executive Officer
(Principal Executive Officer)
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Acorda Therapeutics, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
|
c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
|
d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
|
a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/
Michael Rogers
|
|
Michael Rogers
Chief Financial Officer
(Principal Financial Officer)
|
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|